CD274 and neoplasm: The initial checkpoint inhibitor studies showed a benefit in the second line setting, and in March and June 2015 nivolumab received approval from the US Food and Drug Administration (FDA) and the European Commission (EC) respectively, for second-line treatment of advanced squamous NSCLC, regardless of PD-L1 expression levels on tumor cells [1].